Reach |
-
•
# and % of the total screened who are aged 21+ years, use tobacco, and identify as Alaska Native or American Indian (based on statewide denominator = 27,212) to gauge future dissemination potential.
-
•
Participation rate: # and % of randomized index participants/total eligible.
-
•
Reasons for ineligibility
-
•
Secondary analysis comparing # and % enrolled from different advertisements and sample representativeness (i.e., sex, Alaska region).
|
Advertising; screening and enrollment records; Alaska state tobacco surveys, e.g., BRFSS [1], & census data [38] |
Effectiveness |
Biochemically verified smoking abstinence at 6- and 12-months post treatment. Primary outcome: prolonged abstinence at 12 months post treatment. |
See section 2.6.4
|
Adoption |
Descriptive information from potential future adopting settings (Tribal Health Organization #, type, size) |
Semi-structured interviews conducted at the end of the study |
Implementation (fidelity) |
-
•
% of index participants completing all six smoking status check-ins during the 6-month treatment phase, demographic characteristics associated with fidelity, and trial retention of dyads.
-
•
Description of potential training, workflow, and resource needs and estimates of start-up; implementation costs for future adopting agencies (see cost-effectiveness, below).
|
Intervention process data; baseline and follow-up measures; research team meeting minutes; program tracking records; interviews |
Potential maintenance |
|
Semi-structured interviews conducted at the end of the study |
COST-EFFECTIVENESS |
Potential return on investment |
-
•
Actual program delivery costs: incentives and rewards provided per dyad enrolled; gift cards provided per dyad for the six smoking status check-ins completed, research staff time.
-
•
Intervention costs per index participant quit at 12 months post intervention and estimated health care savings.
|
Program tracking records; data/models from the literature [71] on estimated reduction in annual health care costs for cessation |